Insmed to Host Second Quarter 2009 Conference Call
31 Juillet 2009 - 2:00PM
PR Newswire (US)
RICHMOND, Va., July 31 /PRNewswire/ -- Insmed Inc. (NASDAQ:INSM), a
biopharmaceutical company, today announced that it will host a
conference call on Thursday, August 13th, at 8:30 AM ET, to discuss
its financial results for the second quarter 2009. Insmed intends
to issue its quarterly financial results press release before the
market opens on August 13th. To participate in the live conference
call, please dial 866-804-6920 (U.S. callers) or 857-350-1666
(international), and provide passcode 11895624. A live webcast of
the call will also be available at
http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=2357941.
Please allow extra time prior to the webcast to register, download
and install any necessary audio software. The webcast will be
archived for 30 days, and a telephone replay of the call will be
available for seven days, beginning at 11:30 AM ET on August 13th
at 888-286-8010 (U.S. callers) or 617-801-6888 (international),
using passcode 53658791. About Insmed Insmed Inc. is a
biopharmaceutical company with unique protein development
experience and a proprietary protein platform aimed at niche
markets with unmet medical needs. For more information, please
visit http://www.insmed.com/. Forward-Looking Statements This
release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design,
regulatory and business strategies, plans and objectives of
management and growth opportunities for existing or proposed
products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ
materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, we may lack
financial resources to complete development of product candidates,
the FDA may interpret the results of studies differently than us,
competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical
industry may experience negative market trends, our continuing
efforts to develop IPLEX(TM) may be unsuccessful our common stock
could be delisted from the Nasdaq Capital Market and other risks
and challenges detailed in our filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K for
the year ended December 31, 2008. Readers are cautioned not to
place undue reliance on any forward-looking statements which speak
only as of the date of this release. We undertake no obligation to
publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events. Investor Relations
Contact: Brian Ritchie - FD 212-850-5683 Media Contact: Irma
Gomez-Dib - FD 212-850-5761 DATASOURCE: Insmed Inc. CONTACT:
Investor Relations, Brian Ritchie, +1-212-850-5683, , or Media,
Irma Gomez-Dib, +1-212-850-5761, , both of FD for Insmed Inc. Web
Site: http://www.insmed.com/
Copyright
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024